Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Jing-Jin Electric Technologies
688280
5
Hangzhou Anysoft Information Technology
300571
US Stock MarketDetailed Quotes
AXSM Axsome Therapeutics
- 110.560
- +3.320+3.10%
Trading Apr 29 14:37 ET
5.39BMarket Cap-18.46P/E (TTM)
111.420High107.215Low323.81KVolume107.615Open107.240Pre Close35.64MTurnover0.88%Turnover RatioLossP/E (Static)48.77MShares139.13052wk High94.58P/B4.05BFloat Cap64.11052wk Low--Dividend TTM36.67MShs Float139.130Historical High--Div YieldTTM3.92%Amplitude1.940Historical Low110.060Avg Price1Lot Size
Axsome Therapeutics News
Axsome Therapeutics Price Target Raised to $193.00/Share From $190.00 by RBC Capital
Axsome Therapeutics Is Maintained at Outperform by RBC Capital
Axsome Therapeutics Analyst Ratings
Analysts Are Bullish on These Healthcare Stocks: Axsome Therapeutics (AXSM), Alnylam Pharma (ALNY)
RBC Raises Price Target on Axsome Therapeutics to $193 From $190, Keeps Outperform Rating
Morgan Stanley Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $190
Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK), Axsome Therapeutics (AXSM) and Greenwich LifeSciences (GLSI)
William Blair Maintains Axsome Therapeutics(AXSM.US) With Buy Rating
William Blair Maintains Axsome Therapeutics(AXSM.US) With Buy Rating
Jefferies Initiates Coverage On Axsome Therapeutics With Buy Rating, Announces Price Target of $200
Jefferies Initiates Axsome Therapeutics(AXSM.US) With Buy Rating, Announces Target Price $200
H.C. Wainwright Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $200
RBC Capital Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Cuts Target Price to $190
Axsome Therapeutics Price Target Maintained With a $200.00/Share by HC Wainwright & Co.
Axsome Therapeutics Analyst Ratings
RBC Trims Price Target on Axsome Therapeutics to $190 From $192, Keeps Outperform Rating
A Quick Look at Today's Ratings for Axsome Therapeutics(AXSM.US), With a Forecast Between $153 to $216
Axsome Therapeutics: Promising Market Opportunity for Solriamfetol in Severe EDS Subgroup Boosts Buy Rating
Mizuho Securities Remains a Buy on Axsome Therapeutics (AXSM)
Needham Reiterates Buy on Axsome Therapeutics, Maintains $153 Price Target
Market Insights
Discussing
2025 Buffett shareholders' meeting: What's the new buzz in value investing?
🎙️Discussion 1. In the face of market changes, do you prefer to stick with growth stocks or switch to value stocks? 2. Based on the current
Moomoo News Global
Apr 28 18:10
Warren Buffett Stands Tall as U.S. Stocks Tumble: How the 'Oracle' Is Tackling Tariff Impacts
Discussing
FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma
Moo Live
Mar 20 02:25
FOMC Press Conference, March 19, 2025
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now
